Biotech Values

[genisi]

Depends again on how well can the assay predict the PML risk, but I expect that JCV Ab positive MS patients will not be candidates for 1st line and when/if receive Tysabri will need tight monitoring and perhaps shorter periods of treatment and drug holidays. Good chance that by 2011 this group of patients will have another option after failing ABCRs and before considering Tysabri - Gilenia (FTY720).